| Neuromyelitis Optica Spectrum Disorder |
ChiCTR1900027024: A Phase I Clinical Trial of BAT4406 Injection on the Safety, Tolerability and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1 | 48 | | BAT4406F, 50mg, Intravenous infusion ;BAT4406F, 100mg, Intravenous infusion ;BAT4406F, other doses are to be administered depending on the circumstances, Intravenous infusion ;BAT4406F, 20mg, Intravenous infusion | Huashan Hospital affiliated to Fudan University; Bio-thera Solutions, Ltd., self-finance | Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China. |
|
|
| Recruiting | 1 | 18 | | HBM9161 | The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd | Neuromyelitis optica spectrum disorders | | | | |
| Completed | 1 | 70 | RoW | LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo | Guangzhou Lupeng Pharmaceutical Company LTD. | Multiple Sclerosis, NMO Spectrum Disorder | 11/22 | 12/22 | | |
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1 | 15 | RoW | BAT4406F | Bio-Thera Solutions | Neuromyelitis Optica Spectrum Disorders | 03/23 | 06/23 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/24 | 12/24 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
CAR-AID, NCT06249438: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy |
|
|
| Recruiting | 1 | 30 | RoW | CD20/BCMA-directed CAR-T cells, C-CAR168 | RenJi Hospital, AbelZeta Pharma Inc. | Systemic Lupus Erythematosus (SLE), Immune-Mediated Necrotizing Myopathy, Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis-Relapsing-Remitting | 03/27 | 03/40 | | |
ChiCTR2200057880: A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder |
|
|
| Not yet recruiting | 1 | 23 | | Orelabrutinib, orally, 50 mg QD | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Beijing InnoCare Pharma Tech Co., Ltd. | Neuromyelitis optica spectrum disorder | | | | |
NCT05828212: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica |
|
|
| Recruiting | 1 | 9 | RoW | CD19 CAR-T cells injection | Zhejiang University | Neuromyelitis Optica | 04/26 | 04/26 | | |
